PCN140 - Cost-Effectiveness Analysis of Bevacizumab, Fotemustine and Extended-Dose Temozolomide in Patients with Recurrent Glioblastoma in Spain

Autor: Garcia Lopez, J.L., Rodriguez, Barrios J.M., Puig-Junoy, J., Carrato, Mena A.
Zdroj: In Value in Health November 2014 17(7):A638-A638
Databáze: ScienceDirect